Eli Casdin founded Casdin Capital in 2011 after nearly ten years spent focused on disruptive technologies and business models in life sciences and healthcare, including authoring the black book, The Dawn of Molecular Medicine. Prior to founding Casdin Capital, he was a vice president and analyst at Alliance Bernstein and a member of its “thematic” based investment group, responsible for researching and investing in the implications of new technologies for the life science and healthcare sectors. His early experience includes time at Bear Stearns and at Cooper Hill Partners, one of the earliest biotechnology focused investment firms.
Mr. Casdin earned his bachelor’s degree from Columbia University and his MBA from Columbia Business School. He serves on the Columbia University School of General Studies Board of Directors.